Back on March 27, 2014, I recommended that Money Morning Members pick up what I felt was the very best play in the burgeoning cannabis biotech industry.
Today, the shares have done even better than I imagined, which is why I wanted to touch base with you again.
Right now, we're going to see how it's performed, but, even better, how to maximize the "free trade" it's about to give us.
And if you missed this stock last year – no worries. We'll start you now as it continues its run – a run that took off while "popular" medical marijuana stocks cratered.
Here's how we'll do it…
There's Still Plenty of Upside Left for Us
If you missed that earlier article, let me cut to the chase and tell you what the pick was: GW Pharmaceuticals Plc. (Nasdaq ADR: GWPH).
Based in the UK, this biopharmaceutical firm is developing a broad range of medicines. Its main product is Sativex, a treatment for multiple sclerosis-related ailments and cancer pain.
But before I get into the cutting-edge products that propelled GWPH stock to date – and will keep it moving forward – let's look quickly at how it's done for us following Monday's close.
That Thursday back in March 2014, it closed at $60.26. Along with the broader market, it's down these past few days. But as of Monday's close, it was still just above $113. That's good for more than 86% in gains since we called it.
And I believe it still has plenty of upside left. In fact on June 25, it had an intraday high of over 100% from my original report.
So after the market's recent slide, I think we'll see another rally in this market leader.
Since our goal is to outperform the market, I like for my readers at Money Morning to see exactly how we're measuring up.
Now, here's where the numbers for GW get really exciting…
If you'd simply invested in an S&P index fund on the same day I recommended GW Pharma, you'd be looking at a roughly 11.8% return.
Our 86% profit means we outperformed the overall market by some 628%.
But don't worry, it's not too late to get in. Here's the thing: The market for cannabis products is still taking off. But as in any other sector, not all stocks will be winners.
And that's where my 30 years' experience as a tech investor comes in to play. See, I also know which stocks to avoid.
To illustrate that point, let's take a quick look at how the stocks I said were weaker candidates have done against GWPH.
How We'll Tap Our Experience (and GW's Science) to Profit
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.